Pfizer has significantly reduced its equity stake in
Haleon, in a series of strategic sales, collectively surpassing $3 billion, thereby reducing its ownership to
7.3%. Further,
Morgan Stanley has reduced the stock price for Haleon to $10.05. On the flip side, executives of Haleon have taken steps to acquire shares under a reward plan. This executive move and increased
investment from
BlackRock perhaps indicate a positive future for the company. Meanwhile,
Jefferies continues to maintain a 'buy' rating on the Haleon stock. Haleon has initiated strategic measures, such as a
stock buyback plan and restructuring the board, to strengthen its stock value. Haleon is also prioritizing
product innovation through a hefty investment in a US R&D center, while it simultaneously navigates various changes in major shareholder holdings. Furthermore, Haleon is expanding its influence in the Chinese market while it witnesses shifts in BlackRock Holdings. Despite certain growth concerns and strong competition, Haleon remains favored for its potential top-line growth.
Haleon Stocks News Analytics from Mon, 18 Mar 2024 07:00:00 GMT to Tue, 18 Feb 2025 08:00:00 GMT -
Rating -2
- Innovation 8
- Information 7
- Rumor 5
